
Specific types of cancer—such as bone, kidney, throat, and uterine—also had a higher incidence of chronic and severe pain that restricted daily activity.

Specific types of cancer—such as bone, kidney, throat, and uterine—also had a higher incidence of chronic and severe pain that restricted daily activity.

Certain HER2-positive breast cancers may benefit from anti-HER2 therapy alone without the need for chemotherapy.

Top news of the day from across the health care landscape.

Colon cancer may spread to other parts of the body before original tumors are clinically detectable.

Top news of the day from across the health care landscape.

Pembrolizumab is already an established treatment option for non-small cell lung cancer, with several approved indications for its use in the disease.

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

Officials with the FDA approved Amgen’s trastuzumab-anns, also known as ABP 980 (Kanjinti), the fifth FDA-approved biosimilar referencing trastuzumab (Herceptin).

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

An unhealthy microbiome caused by chronic antibiotic treatment could result in long-term inflammation within the tissue and tumor environment.

Top news of the week from Specialty Pharmacy Times.

Breast cancers with somatic or germline BRCA 1/2 mutations may not be as responsive to checkpoint inhibitors as previously thought.

Top news of the day from across the health care landscape.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Thomas Jefferson University discusses how pharmacist-led interventions help to reduce adverse events associated with polypharmacy in geriatric patients during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, references the ENESTop 192-week study results in which treatment-free remission was achieved in patients with chronic myeloid leukemia in chronic phase after stopping second-line nilotinib.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Jefferson University, discusses how pharmacists can counsel geriatric patients who may be taking multiple medications for chronic illnesses during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

The Impassion130 trial evaluated whether atezolizumab plus nanoparticle albumin-bound paclitaxel increased overall survival in patients with triple negative breast cancer when compared to chemotherapy alone.

During the American Society of Clinical Oncology Annual Meeting in Chicago, IL, Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how growth in the oncology space will affect how pharmacists practice.

Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, discusses his recommendations for pharmacists who may be counseling a patient with chronic myeloid leukemia during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

For some patients, stereotactic body radiation therapy may provide an enhanced quality of life, better efficacy, and reduced adverse effects.

Top news of the day from across the health care landscape.

Findings presented at the 2019 ASCO meeting show venetoclax plus obinutuzumab induced deep, high, and long-lasting minimal residual disease negativity in chronic lymphocytic leukemia.

At the 2019 American Society of Clinical Oncology Annual Meeting, Michael Atkins, MD, director at the Georgetown Lombardi Cancer Center, discussed what pharmacists should know about nivolumab/ipilimumab combination therapy in advanced melanoma.

Top news of the day from across the health care landscape.

Researchers studied the quality of life, pain, Global Health Status, and adverse effects.

A study investigates whether a high-dose of vitamin D with or without exercise is a safe, effective option to prevent bone loss.

Expanded Medicare under the Affordable Care Act nearly eliminated racial disparities in access to timely cancer treatment between African American and white patients.

Daily servings of fruits, vegetables, and grains associated with a lower risk of death from breast cancer.